{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:13:30Z","timestamp":1790435610061,"version":"4.1.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Single-nucleotide polymorphisms (SNPs) have been shown to influence Fc\u03b3 receptor (Fc\u03b3R) affinity and activity, but their effect on treatment response is unclear. We assessed their importance in the efficacy of obinutuzumab or rituximab combined with chemotherapy in untreated advanced follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in the GALLIUM (www.clinicaltrials.gov #NCT01332968) and GOYA (#NCT01287741) trials, respectively. Genomic DNA was extracted from patients enrolled in GALLIUM (n = 1202) and GOYA (n = 1418). Key germline SNPs, FCGR2A R131H (rs1801274), FCGR3A F158V (rs396991), and FCGR2B I232T (rs1050501), were genotyped and assessed for their impact on investigator-assessed progression-free survival (PFS). In both cohorts there was no prognostic effect of FCGR2A or FCGR3A. In FL, FCGR2B was associated with favorable PFS in univariate and multivariate analyses comparing I232T with I232I, with a more modest association for rituximab-treated (univariate: hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.54-1.14; P = .21) vs obinutuzumab-treated patients (HR, 0.56; 95% CI, 0.34-0.91; P = .02). Comparing T232T with I232I, an association was found for obinutuzumab (univariate: HR, 2.76; 95% CI, 1.02-7.5; P = .0459). Neither observation retained significance after multiple-test adjustment. FCGR2B was associated with poorer PFS in multivariate analyses comparing T232T with I232I in rituximab- but not obinutuzumab-treated patients with DLBCL (HR, 4.40; 95% CI, 1.71-11.32; P = .002; multiple-test\u2013adjusted P = .03); however, this genotype was rare (n = 13). This study shows that Fc\u03b3R genotype is not associated with response to rituximab\/obinutuzumab plus chemotherapy in treatment-naive patients with advanced FL or DLBCL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003985","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T15:58:42Z","timestamp":1627574322000},"page":"2935-2944","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Single-nucleotide Fc\u03b3 receptor polymorphisms do not impact obinutuzumab\/rituximab outcome in patients with lymphoma"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0972-2881","authenticated-orcid":false,"given":"Jonathan C.","family":"Strefford","sequence":"first","affiliation":[{"name":"School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Nowicka","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal E.","family":"Hargreaves","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom;"},{"name":"Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Burton","sequence":"additional","affiliation":[{"name":"Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Davies","sequence":"additional","affiliation":[{"name":"Southampton Cancer Research United Kingdom (CRUK)\/National Institute of Health Research (NIHR) Experimental Cancer Medicines Centre, University of Southampton, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind","family":"Ganderton","sequence":"additional","affiliation":[{"name":"Southampton University Hospitals National Health Service (NHS) Foundation Trust, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Ludwig-Maximilians University Hospital Munich, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisako","family":"Iriyama","sequence":"additional","affiliation":[{"name":"Department of Pathology and Tumor Biology, Nagoya Graduate School of Medicine, Nagoya University, Nagoya, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-4117","authenticated-orcid":false,"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, University of Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate V.","family":"Latham","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Martelli","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Section of Hematology, Sapienza University, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farheen","family":"Mir","sequence":"additional","affiliation":[{"name":"Royal Marsden Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Parker","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Potter","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1064-5350","authenticated-orcid":false,"given":"Matthew J. J.","family":"Rose-Zerilli","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"BC Cancer Centre for Lymphoid Cancer;"},{"name":"Department of Medicine, University of British Columbia, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6952-6073","authenticated-orcid":false,"given":"Marek","family":"Trn\u011bn\u00fd","sequence":"additional","affiliation":[{"name":"1st Department of Medicine, 1st Faculty of Medicine, Charles University General Hospital, Prague, Czech Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7772-2747","authenticated-orcid":false,"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[{"name":"Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Bolen","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Klein","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Zurich, Roche Glycart AG, Schlieren, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Knapp","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel Z.","family":"Oestergaard","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2077-089X","authenticated-orcid":false,"given":"Mark S.","family":"Cragg","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom;"},{"name":"Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, University of Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"issue":"10","key":"2021072915350171500_B1","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1182\/blood-2008-04-149161","article-title":"Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation","volume":"112","author":"Beers","year":"2008","journal-title":"Blood."},{"issue":"22","key":"2021072915350171500_B2","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood."},{"issue":"10","key":"2021072915350171500_B3","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in\u00a0vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Mol Cancer Ther."},{"issue":"20","key":"2021072915350171500_B4","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1182\/blood-2013-05-504043","article-title":"Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab","volume":"122","author":"Golay","year":"2013","journal-title":"Blood."},{"issue":"17","key":"2021072915350171500_B5","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2010-07-296913","article-title":"Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies","volume":"117","author":"Alduaij","year":"2011","journal-title":"Blood."},{"issue":"14","key":"2021072915350171500_B6","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med."},{"issue":"12","key":"2021072915350171500_B7","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med."},{"issue":"8","key":"2021072915350171500_B8","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"2021072915350171500_B9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/imr.12342","article-title":"Fc\u03b3R requirements leading to successful immunotherapy","volume":"268","author":"Dahal","year":"2015","journal-title":"Immunol Rev."},{"key":"2021072915350171500_B10","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3389\/fimmu.2017.01245","article-title":"Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?","volume":"8","author":"Marshall","year":"2017","journal-title":"Front Immunol."},{"issue":"1","key":"2021072915350171500_B11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.12341","article-title":"Fc\u03b3 receptors: genetic variation, function, and disease","volume":"268","author":"Hargreaves","year":"2015","journal-title":"Immunol Rev."},{"issue":"4","key":"2021072915350171500_B12","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.4049\/jimmunol.147.4.1338","article-title":"A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding","volume":"147","author":"Warmerdam","year":"1991","journal-title":"J Immunol."},{"issue":"3","key":"2021072915350171500_B13","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V90.3.1109","article-title":"Fc gammaRIIIa-158V\/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L\/R\/H phenotype","volume":"90","author":"Koene","year":"1997","journal-title":"Blood."},{"issue":"5","key":"2021072915350171500_B14","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1172\/JCI119616","article-title":"A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease","volume":"100","author":"Wu","year":"1997","journal-title":"J Clin Invest."},{"issue":"19","key":"2021072915350171500_B15","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1093\/hmg\/ddi320","article-title":"FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling","volume":"14","author":"Kono","year":"2005","journal-title":"Hum Mol Genet."},{"key":"2021072915350171500_B16","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3389\/fimmu.2019.00390","article-title":"Impact of human Fc\u03b3R gene polymorphisms on IgG-triggered cytokine release: critical importance of cell assay format","volume":"10","author":"Hussain","year":"2019","journal-title":"Front Immunol."},{"issue":"3","key":"2021072915350171500_B17","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood."},{"issue":"21","key":"2021072915350171500_B18","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol."},{"issue":"10","key":"2021072915350171500_B19","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","article-title":"Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"16","author":"Ghielmini","year":"2005","journal-title":"Ann Oncol."},{"issue":"4","key":"2021072915350171500_B20","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/1078-0432.CCR-15-1848","article-title":"Fc gamma receptor 3A and 2A polymorphisms do not predict response to rituximab in follicular lymphoma","volume":"22","author":"Kenkre","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"13","key":"2021072915350171500_B21","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1182\/blood-2012-05-431825","article-title":"Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms","volume":"120","author":"Ghesqui\u00e8res","year":"2012","journal-title":"Blood."},{"issue":"8","key":"2021072915350171500_B22","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3324\/haematol.11288","article-title":"FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin\u2019s lymphoma patients treated with sequential CHOP and rituximab","volume":"92","author":"Carlotti","year":"2007","journal-title":"Haematologica."},{"issue":"8","key":"2021072915350171500_B23","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3109\/10428194.2011.574760","article-title":"Fc\u03b3RIIA and Fc\u03b3RIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma","volume":"52","author":"Fabisiewicz","year":"2011","journal-title":"Leuk Lymphoma."},{"issue":"4","key":"2021072915350171500_B24","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hon.2305","article-title":"FCGR3A\/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts","volume":"35","author":"Ghesqui\u00e8res","year":"2017","journal-title":"Hematol Oncol."},{"issue":"7","key":"2021072915350171500_B25","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3324\/haematol.10327","article-title":"FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma","volume":"92","author":"Mitrovi\u00e7","year":"2007","journal-title":"Haematologica."},{"issue":"6","key":"2021072915350171500_B26","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3324\/haematol.2011.050419","article-title":"Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone","volume":"97","author":"Persky","year":"2012","journal-title":"Haematologica."},{"issue":"19","key":"2021072915350171500_B27","doi-asserted-by":"crossref","first-page":"9771","DOI":"10.1158\/0008-5472.CAN-06-0324","article-title":"Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma","volume":"66","author":"Wang","year":"2006","journal-title":"Cancer Res."},{"issue":"20","key":"2021072915350171500_B28","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1182\/blood-2010-03-272765","article-title":"Effect of FCGR2A and FCGR3A variants on CLL outcome","volume":"116","author":"Dornan","year":"2010","journal-title":"Blood."},{"issue":"8","key":"2021072915350171500_B29","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood-2006-01-009480","article-title":"FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma","volume":"108","author":"Kim","year":"2006","journal-title":"Blood."},{"issue":"9","key":"2021072915350171500_B30","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1080\/10428190903128660","article-title":"Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma","volume":"50","author":"Weng","year":"2009","journal-title":"Leuk Lymphoma."},{"issue":"31","key":"2021072915350171500_B31","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol."},{"key":"2021072915350171500_B32","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-115167","article-title":"Obinutuzumab-based immunochemotherapy prolongs progression-free survival and time to next anti-lymphoma treatment in patients with previously untreated follicular lymphoma: four-year results from the phase III GALLIUM study [abstract]","volume":"132","author":"Townsend","year":"2018","journal-title":"Blood."},{"key":"2021072915350171500_B33","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123433","article-title":"Final analysis of GOYA: a randomized, open-label, phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma [abstract]","volume":"134","author":"Sehn","year":"2019","journal-title":"Blood."},{"issue":"11","key":"2021072915350171500_B34","doi-asserted-by":"crossref","first-page":"e0142379","DOI":"10.1371\/journal.pone.0142379","article-title":"Evaluation of high-throughput genomic assays for the Fc gamma receptor locus [published correction appears in PLoS One. 2016;11(3):e0145040.]","volume":"10","author":"Hargreaves","year":"2015","journal-title":"PLoS One."},{"issue":"4","key":"2021072915350171500_B35","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2016-12-759621","article-title":"BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation","volume":"130","author":"Tsuyama","year":"2017","journal-title":"Blood."},{"issue":"1","key":"2021072915350171500_B36","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1038\/s41467-018-06354-3","article-title":"Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma","volume":"9","author":"Arthur","year":"2018","journal-title":"Nat Commun."},{"issue":"17","key":"2021072915350171500_B37","doi-asserted-by":"crossref","first-page":"7881","DOI":"10.1073\/pnas.0915133107","article-title":"A defunctioning polymorphism in FCGR2B is associated with protection against malaria but susceptibility to systemic lupus erythematosus","volume":"107","author":"Willcocks","year":"2010","journal-title":"Proc Natl Acad Sci USA."},{"issue":"17","key":"2021072915350171500_B38","doi-asserted-by":"crossref","first-page":"7169","DOI":"10.1073\/pnas.0608889104","article-title":"Systemic lupus erythematosus-associated defects in the inhibitory receptor Fc\u03b3RIIb reduce susceptibility to malaria","volume":"104","author":"Clatworthy","year":"2007","journal-title":"Proc Natl Acad Sci USA."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/15\/2935\/1815378\/advancesadv2020003985.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/15\/2935\/1815378\/advancesadv2020003985.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T21:35:24Z","timestamp":1672954524000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/15\/2935\/476456\/Single-nucleotide-Fc-receptor-polymorphisms-do-not"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,29]]},"references-count":38,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2021,8,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003985","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,29]]}}}